Prime Medicine CFO to Speak at H.C. Wainwright Investor Conference

Prime Medicine's CFO Allan Reine will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024. A live audio webcast of the event will be available on Prime Medicine's website, with a replay available for 90 days.

author-image
Nitish Verma
New Update
Prime Medicine CFO to Speak at H.C. Wainwright Investor Conference

Prime Medicine CFO to Speak at H.C. Wainwright Investor Conference

Allan Reine, M.D., Chief Financial Officer of Prime Medicine, Inc. (Nasdaq: PRME), will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 4:30 p.m. ET. The conference is being held at the NASDAQ in New York, NY.

A live audio webcast of the fireside chat will be available under "Events & Presentations" in the News & Events section of Prime Medicine's website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the presentation.

Why this matters: The development of gene editing therapies has the potential to revolutionize the treatment of genetic diseases, and Prime Medicine's progress in this area could have significant implications for the healthcare industry and patients worldwide. As the company continues to advance its Prime Editing platform, it may lead to new opportunities for treating a wide range of genetic disorders.

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The company is deploying its proprietary Prime Editing platform, a versatile, precise, and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies.

Prime Medicine is currently progressing "a diversified portfolio of investigational therapeutic programs" organized around core areas of focus: hematology and immunology, liver, lung, ocular, and neuromuscular. The company intends to maximize Prime Editing's broad and versatile therapeutic potential to expand beyond the genetic diseases in its initial pipeline, potentially including immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases.

For investor inquiries, contact Hannah Deresiewicz at Stern Investor Relations, Inc. at 212-362-1200 or hannah.deresiewicz@sternir.com. Media inquiries can be directed to Dan Budwick at 1AB via email at dan@1abmedia.com.

Prime Medicine's CFO Allan Reine will highlight the company's progress and future plans at the upcoming H.C. Wainwright Investor Conference in New York. With its cutting-edge Prime Editing platform, Prime Medicine aims to revolutionize the treatment of genetic diseases through precise and efficient gene editing therapies across a range of therapeutic areas.

Key Takeaways

  • Prime Medicine's CFO Allan Reine to present at H.C. Wainwright Investor Conference on May 20, 2024.
  • Live audio webcast and replay available on Prime Medicine's website.
  • Prime Medicine's Prime Editing platform aims to revolutionize genetic disease treatment.
  • Company focuses on hematology, immunology, liver, lung, ocular, and neuromuscular diseases.
  • Prime Medicine seeks to expand into immunological diseases, cancers, and more.